OneSpan's growth remains elusive despite strong Digital Agreements performance and margin expansion. Find out why OSPN stock is a Hold.
UCB has agreed to acquire Candid Therapeutics for up-to-$2.2 billion, in a deal designed to expand the buyer’s presence in ...
Thank you very much, and welcome to Embellence Group's interim report for the first quarter of 2026. My name is Johan Andgren, and I'm the CEO of the group. And together with me today is Karin Liden, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results